Summary

for people ages 18 years and up (full criteria)
at San Diego, California and other locations
study started
estimated completion

Description

Summary

A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.

Official Title

Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options

Details

This is the first study in patients of F901318. Patients with a limited treatment options will be enrolled and treated with F901318 (olorofim) for up to 12 weeks.

Keywords

Invasive Fungal Infections Anti fungal Invasive aspergillosis Rare moulds Infection Communicable Diseases Mycoses Olorofim

Eligibility

You can join if…

Open to people ages 18 years and up

  • Male and female aged 18 or older whom have given informed consent
  • Ability to comply with the protocol
  • Females must be non lactating and not at risk of pregnancy
  • Patients with invasive fungal disease
  • Patients who have limited alternative treatment options

You CAN'T join if...

  • Women who are pregnant or breast feeding
  • Known history of allergy hypersensitivity to any study drug components
  • Patients with chronic aspergillosis
  • HIV patients who are not receiving antiretroviral therapy
  • Previously enrolled patients or patients enrolled in any clinical trial within the last 30 days
  • Patients with a medical condition that may jeopardize adherence to the protocol or may cause unacceptable additional risk to the patient
  • Patients with predicted short survival time
  • Prohibited concomitant medications

Locations

  • University of California San Diego Medical Center accepting new patients
    San Diego California 92103 United States
  • UC Davis Medical Center accepting new patients
    Sacramento California 95817 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
F2G Ltd.
ID
NCT03583164
Phase
Phase 2
Study Type
Interventional
Last Updated